Emily Bryer Tomasulo, DO
Assistant Professor of Clinical Medicine (Hematology-Oncology)
Attending Physician , Hospital of the University of Pennsylvania
Attending Physician , Pennsylvania Hospital
Program Lead, Cellular and Transplant Program, Pennsylvania Hospital, Pennsylvania Hospital
Department: Medicine
Contact information
230 W Washington Square
Philadelphia, PA 19106
Philadelphia, PA 19106
Education:
BS (Spanish Major, Minors in Psychology and Biology, Honors in Neuroscience)
Schreyer Honors College of The Pennsylvania State University, 2013.
DO (Medicine )
Philadelphia College of Osteopathic Medicine, 2017.
Permanent linkBS (Spanish Major, Minors in Psychology and Biology, Honors in Neuroscience)
Schreyer Honors College of The Pennsylvania State University, 2013.
DO (Medicine )
Philadelphia College of Osteopathic Medicine, 2017.
Selected Publications
Christopher Pleyer, Emily Tomasulo, et. al: Activity and Safety of Venetoclax without Anti-CD20 Lead-in Therapy in Treatment Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood Supplement, American Society of Hematology Annual Meeting, San Diego, CA. Dec 2024 Notes: "Poster Presentation"Emily B. Tomasulo, Dylan Therwhanger, Emeline R. Chong, Mitchell E. Hughes, Michael Fradley, and Stephen J. Schuster: Resolution of ibrutinib-associated hypertension with transition to alternate covalent BTKi Blood Supplement, American Society of Hematology Annual Meeting, San Diego, CA. Dec 2024 Notes: "Poster Presentation"
Emily Tomasulo, Shira Paul, Rui Mu, Xin Tian, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun: Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL. Leukemia & Lymphoma 64(14): 2306-2315. Dec 2023.
Itsara A, Sun C, Bryer E, et al. : Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study. Blood Supplement, American Society of Hematology, Washington, DC Dec 2023 Notes: "Poster Presentation"
Emily Tomasulo: Chronic Lymphocytic Leukemia Chapter Bethesda Handbook of Hematology 2023.
Bryer E, Itsara A, Ahn I et al.: Ibrutinib-associated sudden death in patients with CLL. Blood, American Society of Hematology, Orlando, FL. 140(Supplement 1), Dec 2022 Notes: "Poster Presentation"
Bryer EJ, Destefano C, Kazandjian D.: Current and prospective antibody-based therapies in multiple myeloma Semin Oncol 49(1): 41-47, Feb 2022.
Bryer EJ, Stein E, Goldberg S.: Multivessel Coronary Artery Disease. Mayo Clinic Proceedings: Innovations, Quality, and Outcomes. Dec 2020 Notes: https://mcpiqojournal.org/action/showPdf?pii=S2542-4548%2820%2930150-8.
Bryer E, Dew A, Hill E, et al.: A phase II pilot study of avelumab in combination with hypofractionated radiotherapy in patients with relapsed refractory multiple myeloma. Blood 136(Supplement 1), Nov 2020 Notes: https://ashpublications.org/blood/article/136/Supplement%201/10/473693/A-Phase-II-Pilot-Study-of-Avelumab-in-Combination.
Bryer EJ, Kallan MJ, Chiu TS.: A Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy- Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration. EJHaem 1(1): 35-43, May 2020.